ClinicalTrials.gg
RecruitingNCT05539859NESICHUpdated Nov 16, 2026

Efficacy and Safety of NeuroEndoscopic Surgery for IntraCerebral Hemorrhage

An interventional study of Endoscopic surgery and Medical management in Intracerebral Hemorrhage Basal Ganglia, sponsored by Southwest Hospital, China. Recruiting at 4 sites in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by Southwest Hospital, China · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Nov 2022; still recruiting 4 years later.
Updated Nov 16, 2026Primary completion movedStudy completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
560
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 123 studies in Cerebral Hemorrhage with a site in China — 59 open to participants now, 62 under way, 5 of them phase 3. Cerebral Hemorrhage · China.

Planned enrollment
17th of 77
560 · median 180
Started
2022
with 6 others
No phase
35 of 123
22 open now
Primary completion
2028-06
later than 43 of 61 live
Registered
58th of 123
by date
Lead sponsor
3 of 123
Southwest Hospital, China

Among the 123 studies in Cerebral Hemorrhage with a site in China, this one is the 17th largest by planned enrollment of the 77 interventional ones that give a count, is one of 7 that started in 2022, is one of 35 with no phase, reaches primary completion later than 43 of the 61 other live ones, and was the 58th registered.

Cerebral Hemorrhage

458 studies on the registry are indexed under Cerebral Hemorrhage; 173 are open to participants now.

Browse Cerebral Hemorrhage studies →

Open to participants now

59 of the 123 studies in Cerebral Hemorrhage with a site in China are open now. Recruiting first, the newest first:

54 more — sign in →

All 59 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 115 Cerebral Hemorrhage studies recruiting now, 61 (53%) set no upper age limit and 9 (8%) stop at 75 or younger; 4 take children under 18; 6 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 123 studies in Cerebral Hemorrhage with a site in China, or all of them as a file.
02

Study summary

To compare the efficacy and safety of neuroendoscopic hematoma removal and standard conservative treatment for patients with spontaneous supratentorial deep intracerebral hemorrhage.

Read the detailed description

Neuroendoscopic treatment of spontaneous intracerebral hemorrhage (ICH) is more and more widely used, but multi-center clinical study on the efficacy and safety of neuroendoscopic treatment of ICH is relatively small. Based on the lack of sufficient clinical evidence, the investigators plan to conduct a prospective, multicenter, randomized controlled clinical trial to investigate the safety and efficacy of neuroendoscopy in the treatment of spontaneous cerebral parenchymal hemorrhage, so as to provide evidence-based medical evidence for endoscopic minimally invasive treatment of cerebral hemorrhage and its application.The aim of trial was to determine whether the endoscopic surgery could achieve the benefits of clot evacuation and improve functional outcome at 180 days after ICH without procedure-related safety events or additional brain injury beyond the risks associated with standard care

03

Conditions studied

  • Intracerebral Hemorrhage Basal Ganglia

Browse trials for

Keywords

  • Intracerebral hemorrhage
  • NeuroEndoscopic Surgery
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age 18-80 years, either sex.
  2. Time from onset to the first diagnostic CT within 24 hours (for those without bystanders and with unknown onset time, use the last known time the patient was in good condition)
  3. Deep (external capsule, putamen, internal capsule, caudate nucleus) supratentorial cerebral hemorrhage with a hematoma volume ≥ 25 ml.
  4. Stability of the hematoma determined by two CT scans at different times after onset. If the hematoma enlarges 5ml then the stability of the hematoma can be detected by CT again after 6 hours until the randomization time window is closed.
  5. Pre-randomization GCS score of 5-14 and/or NIHSS score of ≥6.
  6. Pre-onset Modified Rankin Scale (mRS) score 0 or 1.
  7. Blood pressure recorded 6 hours prior to randomization consistently controlled at 180 mmHg or less.
  8. Randomization completed within 24 hours after the first diagnostic CT, and surgical intervention should be performed as soon as possible, no later than 6 hours after randomization, that is to say, surgery should be performed no later than 54 hours after onset.
  9. Informed and voluntarily signed by the patient or family.

Exclusion criteria

Exclusion Criteria:

  1. Hemorrhage clinically diagnosed as a result of cerebral aneurysm, cerebrovascular malformation, moyamoya disease, traumatic brain injury, brain tumor, hemorrhagic transformation of a large cerebral infarct, coagulation dysfunction.
  2. Lobar hemorrhages, thalamic hemorrhages, primary ventricular hemorrhages, cerebellum hemorrhages and brain stem hemorrhages.
  3. Hematoma involving the midbrain, with dilated or unresponsive pupils.
  4. Hematoma producing life-threatening occupying effects (e.g., CT showing midline deviation of more than 1 cm, loss of cisterna ambiens) or patients who are extremely unstable and unfit for enrollment.
  5. count \<100×10\^9/L, (INR) >1.4.
  6. Hematoma extension to ventricle and completely blocked the third or fourth ventricle.
  7. Recent history of cerebral hemorrhage (less than 1 year).
  8. Severe hepatic impairment with 3 times the , or AST 3 times the upper limit of normal. Severe renal insufficiency with less than 30 ml/min/1.73 m2.
  9. Blood pressure not effectively controlled to less than 180 mmHg despite aggressive antihypertensive therapy prior to randomization.
  10. Patients with severe advanced cognitive impairment (e.g. AD) or psychiatric disorders who are unable to complete the follow-up program as required.
  11. Comorbid other serious diseases such as respiratory, circulatory, digestive, urological, endocrine, immune and hematologic disorders.
  12. Pregnant or lactating women, or those who expect to become pregnant within one year.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
560 participants (estimated)

Study arms

  • Experimental
    Experimental Arm

    Endoscopic surgery

    Procedure: Endoscopic surgery

  • Active comparator
    Control Arm

    Medical management

    Other: Medical management

Interventions

  • ProcedureEndoscopic surgery

    Subjects will receive surgical hematoma evacuation using neuroendoscope, followed by medical management

  • OtherMedical management

    Subjects will initially receive the standard medical therapies for the treatment of intracerebral hemorrhage, according to the latest available guideline.

06

What researchers measure

Primary outcomes

  1. The proportion of patients with Modified Rankin Scale (mRS) score 0-3

    Functional outcome (comparing the intervention group to the control), assessed with the modified Rankin Scale (mRS) at 6 months.The mRS is a commonly used scale for measuring the degree of disability or dependence in the daily activities of people who have suffered a stroke or other causes of neurological disability. It is scored from: 0=No symptoms at all, 1=No significant disability, 2=Slight disability, 3=Moderate disability, 4=Moderately severe disability, 5=Severe disability and 6=death.

    Time frame: 180 days

  2. Safety outcome

    All cause mortality from onset to 180 days

    Time frame: 180 days

Secondary outcomes

  1. Glasgow Outcome Scale Extended (GOS-E)

    GOS-E subdivides the categories of severe and moderate disability and good recovery using a scale of 1 to 8 where 1 = death, 2 = vegetative state, 3 = lower severe disability, 4 = upper severe disability, 5 = lower moderate disability, 6 = upper moderate disability, 7 = lower good recovery, and 8 = upper good recovery. Structured telephone interviews have been developed and validated for the GOS-E and these questions were incorporated into the follow-up survey. GOS-E was dichotomized into unfavorable (1 to 4) and favorable (5 to 8) outcomes.

    Time frame: 30 days.

  2. Glasgow Outcome Scale Extended (GOS-E)

    GOS-E subdivides the categories of severe and moderate disability and good recovery using a scale of 1 to 8 where 1 = death, 2 = vegetative state, 3 = lower severe disability, 4 = upper severe disability, 5 = lower moderate disability, 6 = upper moderate disability, 7 = lower good recovery, and 8 = upper good recovery. Structured telephone interviews have been developed and validated for the GOS-E and these questions were incorporated into the follow-up survey. GOS-E was dichotomized into unfavorable (1 to 4) and favorable (5 to 8) outcomes.

    Time frame: 90 days.

  3. Glasgow Outcome Scale Extended (GOS-E)

    GOS-E subdivides the categories of severe and moderate disability and good recovery using a scale of 1 to 8 where 1 = death, 2 = vegetative state, 3 = lower severe disability, 4 = upper severe disability, 5 = lower moderate disability, 6 = upper moderate disability, 7 = lower good recovery, and 8 = upper good recovery. Structured telephone interviews have been developed and validated for the GOS-E and these questions were incorporated into the follow-up survey. GOS-E was dichotomized into unfavorable (1 to 4) and favorable (5 to 8) outcomes.

    Time frame: 180 days.

  4. Modified Rankin Scale (mRS) Score

    The mRS is a commonly used scale for measuring the degree of disability or dependence in the daily activities of people who have suffered a stroke or other causes of neurological disability. It is scored from: 0=No symptoms at all, 1=No significant disability, 2=Slight disability, 3=Moderate disability, 4=Moderately severe disability, 5=Severe disability and 6=death.

    Time frame: 30 days.

  5. Modified Rankin Scale (mRS) Score

    The mRS is a commonly used scale for measuring the degree of disability or dependence in the daily activities of people who have suffered a stroke or other causes of neurological disability. It is scored from: 0=No symptoms at all, 1=No significant disability, 2=Slight disability, 3=Moderate disability, 4=Moderately severe disability, 5=Severe disability and 6=death.

    Time frame: 90 days .

  6. Survival rate

    comparing the intervention group to the control

    Time frame: 30 days.

  7. Survival rate

    comparing the intervention group to the control

    Time frame: 90 days.

  8. Assessment of cognitive function with Mini-Mental State Examination (MMSE)

    The MMSE is a screening test for cognitive dysfunction. The test consists of five sections (orientation, registration, attention-calculation, recall, and language); the total score can range from 0 to 30, with a higher score indicating better function.

    Time frame: 30 days.

  9. Assessment of cognitive function with Mini-Mental State Examination (MMSE)

    The MMSE is a screening test for cognitive dysfunction. The test consists of five sections (orientation, registration, attention-calculation, recall, and language); the total score can range from 0 to 30, with a higher score indicating better function.

    Time frame: 90 days.

  10. Assessment of cognitive function with Mini-Mental State Examination (MMSE)

    The MMSE is a screening test for cognitive dysfunction. The test consists of five sections (orientation, registration, attention-calculation, recall, and language); the total score can range from 0 to 30, with a higher score indicating better function.

    Time frame: 180 days.

  11. Quality of life measured with the 5-level EQ-5D (EQ-5D-5L)

    The EQ-5D-5L is a standard measure of health-related quality of life.EQ-5D-5L consists of two components: a health state profile and a visual analog scale (VAS). EQ-5D health state profile comprises 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 5 levels: 1=no problems, 2=slight problems, 3=moderate problems, 4=severe problems, and 5=extreme problems. The 5D-5L systems are converted into a single index utility score between 0 to 1, where a higher score indicates a better health state. The VAS records the participant's health on a 0-100 mm VAS scale, with 0 indicating "the worst health you can imagine" and 100 indicating "the best health you can imagine". Higher scores of EQ VAS indicate better health.

    Time frame: 30 days.

  12. Quality of life measured with the 5-level EQ-5D (EQ-5D-5L)

    The EQ-5D-5L is a standard measure of health-related quality of life.EQ-5D-5L consists of two components: a health state profile and a visual analog scale (VAS). EQ-5D health state profile comprises 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 5 levels: 1=no problems, 2=slight problems, 3=moderate problems, 4=severe problems, and 5=extreme problems. The 5D-5L systems are converted into a single index utility score between 0 to 1, where a higher score indicates a better health state. The VAS records the participant's health on a 0-100 mm VAS scale, with 0 indicating "the worst health you can imagine" and 100 indicating "the best health you can imagine". Higher scores of EQ VAS indicate better health.

    Time frame: 90 days.

  13. Quality of life measured with the 5-level EQ-5D (EQ-5D-5L)

    The EQ-5D-5L is a standard measure of health-related quality of life.EQ-5D-5L consists of two components: a health state profile and a visual analog scale (VAS). EQ-5D health state profile comprises 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 5 levels: 1=no problems, 2=slight problems, 3=moderate problems, 4=severe problems, and 5=extreme problems. The 5D-5L systems are converted into a single index utility score between 0 to 1, where a higher score indicates a better health state. The VAS records the participant's health on a 0-100 mm VAS scale, with 0 indicating "the worst health you can imagine" and 100 indicating "the best health you can imagine". Higher scores of EQ VAS indicate better health.

    Time frame: 180 days.

  14. Length of ICU

    Duration of stay in the ICU

    Time frame: Number of days from admission, up to 180 days

  15. Length of hospitalization

    Duration of stay in the hospital

    Time frame: Number of days from admission to discharge, up to 180 days

  16. In-hospital cost

    all medical cost during the in-hospital period

    Time frame: Number of days from admission to discharge, up to 180 days

07

Study locations

4 of 4 sites recruiting
  • chongqing Emergency Medical Center
    Chongqing, Chongqing Municipality 400014, China
    Recruiting
    • Bing y Deng, MD · Contact
  • Xiang Yang NO.1 Peoples Hospital
    Hubei, Hubei 441000, China
    Recruiting
  • Dazhu County People's Hospital
    Sichuan, Sichuan 635100, China
    Recruiting
    • sheng zhu, MD · Contact371773434@qq.com · +8615882911301
    • sheng zhu, MD PHD · Principal investigator
  • Ganzhou city people's Hospita
    Ganzhou, China
    Recruiting
    • Yun X Ye, MD · Contact
08

References and documents

Publications

  • Hansen BM, Ullman N, Muschelli J, Norrving B, Dlugash R, Avadhani R, Awad I, Zuccarello M, Ziai WC, Hanley DF, Thompson RE, Lindgren A; MISTIE and CLEAR Investigators. Relationship of White Matter Lesions with Intracerebral Hemorrhage Expansion and Functional Outcome: MISTIE II and CLEAR III. Neurocrit Care. 2020 Oct;33(2):516-524. doi: 10.1007/s12028-020-00916-4. PubMed 32026447 ↗
  • de Oliveira Manoel AL. Surgery for spontaneous intracerebral hemorrhage. Crit Care. 2020 Feb 7;24(1):45. doi: 10.1186/s13054-020-2749-2. PubMed 32033578 ↗
  • Anderson CD, James ML. Survival and independence after intracerebral hemorrhage: Trends and opportunities. Neurology. 2018 Jun 5;90(23):1043-1044. doi: 10.1212/WNL.0000000000005625. Epub 2018 May 4. No abstract available. PubMed 29728523 ↗
  • Kuo LT, Chen CM, Li CH, Tsai JC, Chiu HC, Liu LC, Tu YK, Huang AP. Early endoscope-assisted hematoma evacuation in patients with supratentorial intracerebral hemorrhage: case selection, surgical technique, and long-term results. Neurosurg Focus. 2011 Apr;30(4):E9. doi: 10.3171/2011.2.FOCUS10313. PubMed 21456936 ↗
  • Kellner CP, Song R, Pan J, Nistal DA, Scaggiante J, Chartrain AG, Rumsey J, Hom D, Dangayach N, Swarup R, Tuhrim S, Ghatan S, Bederson JB, Mocco J. Long-term functional outcome following minimally invasive endoscopic intracerebral hemorrhage evacuation. J Neurointerv Surg. 2020 May;12(5):489-494. doi: 10.1136/neurintsurg-2019-015528. Epub 2020 Jan 8. PubMed 31915207 ↗
  • Xu X, Chen X, Li F, Zheng X, Wang Q, Sun G, Zhang J, Xu B. Erratum. Effectiveness of endoscopic surgery for supratentorial hypertensive intracerebral hemorrhage: a comparison with craniotomy. J Neurosurg. 2018 Feb;128(2):649. doi: 10.3171/2017.5.JNS161589a. Epub 2017 Jul 28. No abstract available. PubMed 28753114 ↗
  • Wang L, Zhou T, Wang P, Zhang S, Yin Y, Chen L, Duan H, Wu N, Feng H, Hu R. Efficacy and safety of NeuroEndoscopic Surgery for IntraCerebral Hemorrhage: A randomized, controlled, open-label, blinded endpoint trial (NESICH). Int J Stroke. 2024 Jun;19(5):587-592. doi: 10.1177/17474930241232292. Epub 2024 Feb 19. PubMed 38291017 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2022 (actual). Primary completion is estimated for Jun 2028, 67 months after the start.

Of 77 non-industry interventional studies with no phase under Cerebral Hemorrhage, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 75. This study's planned 67 months is above that.

Counting every sponsor, half of 85 studies reached it within 38 months; a quarter within 19 and three quarters within 72.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 16, 2026: primary completion Sep 2025 → Jun 2028 and completion Sep 2026 → Dec 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 4, 2022
First posted
Sep 14, 2022
StartActual
Nov 18, 2022
Primary completionEst.
Jun 30, 2028was Sep 2025
CompletionEst.
Dec 31, 2028was Sep 2026
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added, 1 site removed
Show site
  • chongqing Emergency Medical Center · Chongqing, China
Show 1 removed
  • chongqing Emergency Medical Center · Chongqing, China
Nov 16, 2026
Primary completion
Sep 1, 2025→Jun 30, 2028
Nov 16, 2026
Study completion
Sep 1, 2026→Dec 31, 2028
Nov 16, 2026
Publications
1 publication citing this study linked from PubMed, e.g. PubMed 38291017 ↗
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    Publications 1 publication citing this study linked from PubMed, e.g. PubMed 38291017 ↗
    1 site added, 1 site removed
    Show site
    • chongqing Emergency Medical Center · Chongqing, China
    Show 1 removed
    • chongqing Emergency Medical Center · Chongqing, China
    Primary completion Sep 1, 2025→Jun 30, 2028
    Study completion Sep 1, 2026→Dec 31, 2028
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05539859
Lead sponsor
Southwest Hospital, China
Responsible party
Rong Hu, MD (Director of Department of Neurosurgery, Southwest Hospital, China) — Principal investigator
First posted
Sep 14, 2022
Start date
Nov 18, 2022
Primary completion
Jun 30, 2028 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
Nov 16, 2026

Study contacts

Rong Hu, MD
Contact
huchrong@aliyun.com
8615123917123
Hua Feng, MD
Contact
fenghua201818@aliyun.com
8613708321681
Rong Hu, MD
study chair · PLA Army Medical University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion